B cell development: signal transduction by antigen receptors and their surrogates

doi:10.1016/S0952-7915(99)80025-9

Current Opinion in Immunology

Volume 11, Issue 2, April 1999, Pages 143-151

https://doi.org/10.1016/S0952-7915(99)80025-9 Get rights and content

Constitutive signal transduction by B cell antigen-receptors and/or their surrogates appears to be critical for progression through multiple developmental checkpoints and for survival of mature B cells in the periphery. Antigen-induced signaling via the B cell receptor can compensate for defects in constitutive signaling and initiates receptor editing, apoptosis and anergy in normal mice - purging the repertoire of autoreactive cells. Thus development and survival of mature B cells seem to require continuous receptor signaling of a defined amplitude.

References and recommended reading (87)

NagataK. et al.
The Ig alpha/Igbeta heterodimer on mu-negative proB cells is competent for transducing signals to induce early B cell differentiation
Immunity
(1997)
KitamuraD. et al.
Targeted disruption of mu chain membrane axon causes loss of heavy-chain allelic exclusion
Nature
(1992)
KitamuraD. et al.
A B cell-deficient mouse by targeted disruption of the membrane axon of the immunoglobulin mu chain gene
Nature
(1991)
EhlichA. et al.
Immunoglobulin heavy and light chain genes rearrange independently at early stages of B cell development
Cell
(1993)
CaldwellR.G. et al.
Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals
Immunity
(1998)
MelamedD. et al.
Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection
Cell
(1998)
TamirI. et al.
Antigen receptor signaling: integration of protein tyrosine kinase functions
Oncogene
(1998)
FuC. et al.
BLNK: a central linker protein in B cell activation
Immunity
(1998)
FluckigerA.C. et al.
Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation
EMBO J
(1998)
BollardS. et al.
SHIP modulates immune receptor responses by regulating membrane association of Btk
Immunity
(1998)

RickertR.C. et al.

Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice

Nature

(1995)

PapavasiliouF. et al.

The role of Ig beta in precursor B cell transition and allelic exclusion

Science

(1995)

PapavasiliouF. et al.

The cytoplasmic domains of immunoglobulin (Ig) alpha and Ig beta can independently induce the precursor B cell transition and allelic exclusion

J Exp Med

(1995)

UrbanekP. et al.

Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP

Cell

(1994)

FitzsimmonsD. et al.

Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter

Genes Dev

(1996)

TorresR.M. et al.

Aberrant B cell development and immune response in mice with a compromised BCR complex

Science

(1996)

ChengA.M. et al.

Syk tyrosine kinase required for mouse viability and B-cell development

Nature

(1995)

ChanV.W. et al.

Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes

Curr Biol

(1998)

DolmetschR.E. et al.

Differential activation of transcription factors induced by Ca2+ response amplitude and duration

Nature

(1997)

HealyJ.I. et al.

Different nuclear signals are activated by the B cell receptor during positive versus negative signaling

Immunity

(1997)

HardyR.R. et al.

Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow

J Exp Med

(1991)

RolinkA. et al.

IL2 receptor alpha chain (CD25, TAC) expression defines a crucial stage in pre-B cell development

Int Immunol

(1994)

KitamuraD. et al.

A critical role of lambda 5 protein in B cell development

Cell

(1992)

ten BoekelE. et al.

Precursor B cells showing H chain allelic inclusion display allelic exclusion at the level of pre-B cell receptor surface expression

Immunity

(1998)

CarsettiR. et al.

Transitional B cells are the target of negative selection in the B cell compartment

J Exp Med

(1995)

HavranW.L. et al.

mIgM:mlgD ratios on B cells: mean mIgD expression exceeds mIgM by 10-fold on most splenic B cells

J Immunol

(1984)

MombaertsP. et al.

RAG-1-deficient mice have no mature B and T lymphocytes

Cell

(1992)

ShinkaiY. et al.

RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement

Cell

(1992)

CroninF.E. et al.

Role of mu heavy chain in B cell development l. Blocked B cell maturation but complete allelic exclusion in the absence of Ig alpha/beta

J Immunol

(1998)

TiegsS.L. et al.

Receptor editing in self-reactive bone marrow B cells

J Exp Med

(1993)

RetterM.W. et al.

Receptor editing occurs frequently during normal B cell development

J Exp Med

(1998)

Santulli-MarottoS. et al.

Autoreactive B cell regulation: peripheral induction of developmental arrest by lupus-associated autoantigens

Immunity

(1998)

CambierJ.C. et al.

Differential susceptibility of neonatal and adult murine spleen cells to in vitro induction of B-cell tolerance

J Exp Med

(1976)

MetcalfE.S. et al.

In vitro tolerance induction of neonatal murine B cells

J Exp Med

(1976)

DeFrancoA.L.

The complexity of signaling pathways activated by the BCR

Curr Opin lmmunol

(1997)

WienandsI. et al.

SLP-65: a new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation

J Exp Med

(1998)

KolanusW. et al.

T cell activation by clustered tyrosine kinases

Cell

(1993)

KurosakiT. et al.

Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling

J Exp Med

(1995)

BuhlA.M. et al.

Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for P13-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization

J Exp Med

(1997)

FalascaM. et al.

Activation of phospholipase C gamma by Pl 3-kinase-induced PH domain-mediated membrane targeting

EMBO J

(1998)

JiangA. et al.

Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2terminal kinase 1, and p38 mitogen-activated protein kinase

J Exp Med

(1998)

HashimotoA. et al.

Involvement of guanosine triphosphateses and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinese, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor

J Exp Med

(1998)

EngelP. et al.

Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule

Immunity

(1995)

Cited by (161)

At low levels, inorganic mercury interference with antigen signaling is associated with modifications to a panel of novel phosphoserine sites in B cell receptor pathway proteins
2023, Toxicology in Vitro
Epidemiological studies indicate that human and animal exposure to environmental mercury (Hg) disrupts normal immune system function, but the molecular mechanism responsible for this is still unresolved. We have previously utilized phospho-proteomic mass spectrometry to demonstrate that in the absence of B Cell Receptor (BCR) stimulation, exposure of B cells to Hg induces significant changes to a great many elements of the BCR signaling pathway in a concentration dependent manner. In this report, we have extended those initial findings by utilizing mass spectrometry to evaluate in detail the effect of low-level Hg exposure on BCR induced phospho-proteomic changes. Specifically, murine WEHI-231 B lymphoma cells were exposed to environmentally relevant levels of Hg with or without concomitant BCR stimulation. The cellular phospho-proteomes were then profiled by LC-MS/MS. We found that for low-level exposures, Hg interference with signal transduction across the BCR pathway was predominantly associated with modification of phosphorylation of 12 phosphosites located on seven different proteins. Nine sites were serine, two sites tyrosine and one site threonine. Most of these sites are novel, in the sense that only the two tyrosine and one of the serine sites have previously been reported to be associated with BCR signaling.
Replication timing alterations in leukemia affect clinically relevant chromosome domains
2019, Blood Advances
Human B-cell precursor acute lymphoid leukemias (BCP-ALLs) comprise a group of genetically and clinically distinct disease entities with features of differentiation arrest at known stages of normal B-lineage differentiation. We previously showed that BCP-ALL cells display unique and clonally heritable, stable DNA replication timing (RT) programs (ie, programs describing the variable order of replication and subnuclear 3D architecture of megabase-scale chromosomal units of DNA in different cell types). To determine the extent to which BCP-ALL RT programs mirror or deviate from specific stages of normal human B-cell differentiation, we transplanted immunodeficient mice with quiescent normal human CD34⁺ cord blood cells and obtained RT signatures of the regenerating B-lineage populations. We then compared these with RT signatures for leukemic cells from a large cohort of BCP-ALL patients with varied genetic subtypes and outcomes. The results identify BCP-ALL subtype-specific features that resemble specific stages of B-cell differentiation and features that seem to be associated with relapse. These results suggest that the genesis of BCP-ALL involves alterations in RT that reflect biologically significant and potentially clinically relevant leukemia-specific epigenetic changes.
Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies
2019, Blood
This phase 1/2 study assessed parsaclisib (INCB050465), a next-generation, potent, and highly selective phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, in patients with relapsed or refractory B-cell malignancies, alone or in combination with a Janus kinase 1 inhibitor (itacitinib) or chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide). Seventy-two patients received parsaclisib monotherapy (5-45 mg once daily). Expansion doses were 20 and 30 mg once daily; intermittent dosing at 20 mg (once daily for 9 weeks, then once weekly) was explored. No dose-limiting toxicities were identified, and maximum tolerated dose was not reached. Most common nonhematologic treatment-emergent adverse events (TEAEs) were diarrhea/colitis (36%), nausea (36%), fatigue (31%), and rash (31%). Grade 3/4 neutropenia occurred in 19% of patients. Serious TEAEs (>2 patients) were diarrhea/colitis (n = 9), pyrexia (n = 4), hypotension (n = 3), and sepsis (n = 3). Aspartate and alanine transaminase elevations occurring before treatment discontinuation were grade 1, except 1 grade 3 event each, secondary to sepsis. Two patients experienced 3 fatal parsaclisib-unrelated TEAEs (respiratory failure; respiratory failure and sepsis). In non-Hodgkin lymphoma (NHL), objective response rates to monotherapy were 71% in follicular lymphoma, 78% in marginal zone lymphoma, 67% in mantle cell lymphoma, and 30% in diffuse large B-cell lymphoma; 93% of responses occurred at first assessment (∼9 weeks). Parsaclisib has demonstrated antitumor activity in relapsed or refractory B-cell NHL with the potential for improved long-term patient outcomes. Phase 2 studies in relapsed or refractory B-cell NHL subtypes are ongoing. This trial was registered at www.clinicaltrials.gov as #NCT02018861.
B cell MHC class II signaling: A story of life and death
2019, Human Immunology
MHC class II regulates B cell activation, proliferation, and differentiation during cognate B cell-T cell interaction. This is, in part, due to the MHC class II signaling in B cells. Activation of MHC Class II in human B cells or “primed” murine B cells leads to tyrosine phosphorylation, calcium mobilization, AKT, ERK, JNK activation. In addition, crosslinking MHC class II with monoclonal Abs kill malignant human B cells. Several humanized anti-HLA-DR/MHC class II monoclonal Abs entered clinical trials for lymphoma/leukemia and MHC class II-expressing melanomas. Mechanistically, MHC class II is associated with a wealth of transmembrane proteins including the B cell-specific signaling proteins CD79a/b, CD19 and a group of four-transmembrane proteins including tetraspanins and the apoptotic protein MPYS/STING. Furthermore, MHC class II signals are compartmentalized in the tetraspanin-enriched microdomains. In this review, we discuss our current understanding of MHC class II signaling in B cells focusing on its physiological significance and the therapeutic potential.
Phase 1 study of the PI3Kd inhibitor INCB040093 6 JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
2018, Blood
Because both phosphatidylinositol 3-kinase δ (PI3Kδ) and Janus kinase (JAK)-signal transducer and activator of transcription pathways contribute to tumor cell proliferation and survival in B-cell malignancies, their simultaneous inhibition may provide synergistic treatment efficacy. This phase 1 dose-escalation/expansion study assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of INCB040093, a selective PI3Kδ inhibitor, as monotherapy or combined with itacitinib (formerly INCB039110), a selective JAK1 inhibitor, in adult patients with relapsed or refractory (R/R) B-cell lymphomas. Final results are reported. Overall, 114 patients were treated (monotherapy, n = 49; combination therapy, n = 72 [7 patients crossed over from monotherapy to combination]). INCB040093 100 mg twice daily (monotherapy) and INCB040093 100 mg twice daily + itacitinib 300 mg once daily (combination) were the recommended phase 2 doses. One dose-limiting toxicity (gastrointestinal bleed secondary to gastric diffuse large B-cell lymphoma [DLBCL] regression) occurred with monotherapy. The most common serious adverse events with monotherapy were pneumonia (n = 5) and pyrexia (n = 4), and with combination Pneumocystis jiroveci pneumonia (n = 5), pneumonia (unrelated to P jiroveci; n = 5), and pyrexia (n = 4). Grade 3 or higher transaminase elevations were less common with combination. INCB040093 was active across the B-cell lymphomas; 63% of patients (5/8) with follicular lymphoma responded to monotherapy. Adding itacitinib provided promising activity in select subtypes, with responses of 67% (14/21) in classic Hodgkin lymphoma (vs 29% [5/17] with monotherapy) and 31% (4/13) in nongerminal center B-cell-like DLBCL. INCB040093 with/without itacitinib was tolerated and active in this study, and is a promising treatment strategy for patients with select R/R B-cell lymphomas. This trial was registered at www.clinicaltrials.gov as #NCT01905813.
Identification of a secondary promoter within the human B cell receptor component gene hCD79b
2013, Journal of Biological Chemistry
Citation Excerpt :
The activities of these two proteins are essential for the initiation of signal transduction following BCR engagement with an antigen molecule (1). The engaged BCR triggers phosphorylation of these subunits with the subsequent triggering of clonal B cell expansion and production of secreted immunoglobulin (2). The expression of the BCR is repressed during the terminal stages of B cell differentiation, and the CD79b/CD79a encoded proteins are undetectable in terminally differentiated plasma cells (3, 4).
The human B cell-specific protein, CD79b (also known as Igβ and B29) constitutes an essential signal transduction component of the B cell receptor. Although its function is central to the triggering of B cell terminal differentiation in response to antigen stimulation, the transcriptional determinants that control CD79b gene expression remain poorly defined. In the present study, we explored these determinants using a series of hCD79b transgenic mouse models. Remarkably, we observed that the previously described hCD79b promoter along with its associated enhancer elements and first exon could be deleted without appreciable loss of hCD79b transcriptional activity or tissue specificity. In this deletion setting, a secondary promoter located within exon 2 maintained full levels and specificity of hCD79b transcription. Of note, this secondary promoter was also active, albeit at lower levels, in the wild-type hCD79b locus. The activity of the secondary promoter was dependent on the action(s) of a conserved sequence element mapping to a chromatin DNase I hypersensitive site located within intron 1. mRNA generated from this secondary promoter is predicted to encode an Igβ protein lacking a signal sequence and thus unable to serve normal B cell receptor function. Although the physiologic role of the hCD79b secondary promoter and its encoded protein remain unclear, the current data suggest that it has the capacity to play a role in normal as well as pathologic states in B cell proliferation and function.
Transcriptional control of hCD79b is critical to B cell function and poorly understood.
A fully sufficient and novel secondary promoter was identified within intron 1 of hCD79b.
hCD79b has a complex transcriptional structure comprising two competing promoters.
The secondary promoter within hCD79b predicts novel pathways of B cell receptor expression in normal and pathologic settings.

View all citing articles on Scopus

View full text

B cell development: signal transduction by antigen receptors and their surrogates

Immunity

Nature

Nature

Cell

Immunity

Cell

Oncogene

Immunity

EMBO J

Immunity

Nature

Science

J Exp Med

Cell

Genes Dev

Science

Nature

Curr Biol

Nature

Immunity

J Exp Med

Int Immunol

A critical role of lambda 5 protein in B cell development

Cell

Precursor B cells showing H chain allelic inclusion display allelic exclusion at the level of pre-B cell receptor surface expression

Immunity

Transitional B cells are the target of negative selection in the B cell compartment

J Exp Med

mIgM:mlgD ratios on B cells: mean mIgD expression exceeds mIgM by 10-fold on most splenic B cells

J Immunol

RAG-1-deficient mice have no mature B and T lymphocytes

Cell

RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement

Cell

Role of mu heavy chain in B cell development l. Blocked B cell maturation but complete allelic exclusion in the absence of Ig alpha/beta

J Immunol

Receptor editing in self-reactive bone marrow B cells

J Exp Med

Receptor editing occurs frequently during normal B cell development

J Exp Med

Autoreactive B cell regulation: peripheral induction of developmental arrest by lupus-associated autoantigens

Immunity

Differential susceptibility of neonatal and adult murine spleen cells to in vitro induction of B-cell tolerance

J Exp Med

In vitro tolerance induction of neonatal murine B cells

J Exp Med

The complexity of signaling pathways activated by the BCR

Curr Opin lmmunol

SLP-65: a new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation

J Exp Med

T cell activation by clustered tyrosine kinases

Cell

Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling

J Exp Med

Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for P13-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization

J Exp Med

Activation of phospholipase C gamma by Pl 3-kinase-induced PH domain-mediated membrane targeting

EMBO J

Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2terminal kinase 1, and p38 mitogen-activated protein kinase

J Exp Med

Involvement of guanosine triphosphateses and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinese, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor

J Exp Med

Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule

Immunity